Bernardeschi P, Dentico P, Rossi S, Fiorentini G, Giustarini G, Montenora I, Turano E
S Giuseppe General Hospital, Empoli, Italy.
J Chemother. 2004 Nov;16 Suppl 5:90-3. doi: 10.1080/1120009x.2004.11782395.
Thalidomide produces a response rate from 32 to 66% of pre-treated myeloma patients with doses ranging from 100 to 800 mg/daily. Common, dose-related side effects are sedation, constipation, polyneuropathy. Increased incidence of thromboembolic events were observed in myeloma patients receiving thalidomide as front-line therapy or in association with chemotherapy. Less common adverse reactions are central nervous system (CNS) dysfunction and cutaneous reactions. We describe the update of our experience with low dose thalidomide plus monthly high dose dexamethasone and zolendronate. Most patients were able to tolerate this regimen with few side effects. Erythrocyte sedimentation rate (ESR) lowering was early observed in patients who subsequently responded.
沙利度胺对预处理过的骨髓瘤患者的有效率为32%至66%，每日剂量范围为100至800毫克。常见的、与剂量相关的副作用有镇静、便秘、多发性神经病。在接受沙利度胺作为一线治疗或与化疗联合使用的骨髓瘤患者中，观察到血栓栓塞事件的发生率增加。较不常见的不良反应是中枢神经系统（CNS）功能障碍和皮肤反应。我们描述了低剂量沙利度胺联合每月一次高剂量地塞米松和唑来膦酸的经验更新。大多数患者能够耐受该方案，副作用很少。在随后有反应的患者中早期观察到红细胞沉降率（ESR）降低。
